New Therapies, Risk Factors Drive Hepatitis C Diagnostics

New Therapies, Risk Factors Drive Hepatitis C Diagnostics

This blog post discusses findings from Kalorama Information’s just-published market research report, The World Market for Molecular Diagnostics, 7th Edition (Infectious Disease, Cancer, NAT Blood Screening, Transplantation, Histology/Cytology, Inherited Diseases).

Clinical molecular diagnostics does not lack in targets. Dynamic expansion markets in point-of-care testing and cancer have headlined assay development efforts in recent years, but they are not the only major opportunities in molecular diagnostics.


In Nanapore Sequencing, Progress and Lawsuits

In Nanapore Sequencing, Progress and Lawsuits

Several companies are competing in the market and in the courtroom to market a diagnostic platform from nanopore technology. There are noted limitations such as data quality, but also progress. A review of the ongoing push for next-generation sequencing at the nano level.


Smart Photons and Dose-Reducing Software Among Drivers of CT System Market

Smart Photons and Dose-Reducing Software Among Drivers of CT System Market

CT Systems are smarter and faster. They determine how best to limit radiation exposure, image many more slices, and they use latest technologies to limit reflection. product innovations are combating some of the downsides and ensuring future growth, according to Kalorama's new report.

  • by Bruce Carlson
  • January 18 2017
  • IVD


Top 5 News Stories in In Vitro Diagnostics - January 2017

Top 5 News Stories in In Vitro Diagnostics - January 2017

IBM's Watson, new reimbursement rules, Computers bring cancer genomics closer to the clinic, largest liquid biopsy panel eve, DIY paper centrifuges and Zika developments are among the news stories of note for Kalorama this month.


Next-Generation Sequencing: On Our Radar

Kalorama continues to track the sequencing market, which had an estimated $3.8 billion in product revenues in 2015. The market opportunity is evidenced by a number of acquisitions, financing rounds, product launches, and approvals, but six events stand out.


Advanced Staining (IHC, ISH) in Clinical Diagnostics’ Genomic Age

The least glamorous and most labor intensive segment of clinical molecular diagnostic testing, histology and advanced stains such as in situ hybridization (ISH) and immunohistochemistry (IHC) endure even as their markets shift to other lab workflows and emerging IVD technologies.


Healthcare Turns to Mass Spectrometry to Combat Infectious Disease

Healthcare Turns to Mass Spectrometry to Combat Infectious Disease

The concept of breaking down compounds, charging or ionizing them, in order to determine their properties, or mass spectrometry, is a technology first developed several decades ago and cofinded deep in research laboratories. Now it’s becoming as important a testing tool and other in vitro diagnostic analyzers. New improvements in the old technology such as laser desorption and electrospray have made these machines usable for protein and DNA work, and innovative companies have put them to work combating disease threats such as cancer and infectious disease.


Abbott Takes on Pain with St. Jude Acquistion

Abbott Takes on Pain with St. Jude Acquistion

Abbott’s acquisition of St. Paul, MN-based device company St. Jude Medical will impact a number of medical device markets, and place the pharmaceutical and testing giant into a leading position in the medical device industry, Non-medical pain relief is an increasing focus point with attention on the dangers of pain medication and the need to find alternatives to reduce chronic pain,” said Bruce Carlson, Publisher of Kalorama Information. “Abbott builds on its cardiovascular device properties with this deal, and that is a big focus of press coverage. St. Jude’s impressive spinal cord offering should not be obscured in this transaction. according to Kalorama Information. The healthcare market research firm finds that the purchase puts Abbott into the electrostimulation market particularly in neurostimulation, a fast-growing market where St. Jude is one of three top companies.